Replies to post #225335 on Biotech Values

[DewDiligence]

ABUS—They also had a change in leadership a couple days ago. Maybe related?

I don’t think so. Investors don’t care that much who the CEO of ABUS is, but (given the company’s history) investors do worry about ABUS’ clinical programs getting sidelined.

Even after today’s bounce, ABUS is down 75% from its Oct 2018 price before the setbacks on ARB-1467 and AB-452 (#msg-144116381).